VYNDAQEL 61 mg, soft capsule capsule
Active ingredients: Tafamidis
Commercialized according to BDPMDispensing in France: Prescription only
Soft capsulecapsuleorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- VYNDAQEL 61 mg, capsule molle
- Pharmaceutical form
- capsule molle
- Route of administration
- orale
- Presentation description
- plaquettes PVC polyamide aluminium PVC-Aluminium de 30 x 1 capsules (conditionnement unitaire)
- Marketing authorisation holder
- PFIZER EUROPE MA EEIG (BELGIQUE)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 1 Jun 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
61420887CIP73020207CIP133400930202074Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TAFAMIDIScapsule | 61 mg · une capsule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The published catalog does not list other packages of similar medicines.